A vaccine for the new coronavirus may take a year to be available for the public. Credit: Arek Socha from Pixabay.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Biotechnology firm Codagenix has partnered with vaccine manufacturer Serum Institute of India to work together for the development of a vaccine for the new coronavirus.

The partners intend to develop a live-attenuated vaccine, which can induce an immune response to different antigens of the virus and enables scale for mass production, among other benefits.

Viral deoptimisation quickly synthesises live-attenuated vaccines. The company only requires information about the viral genome’s digital sequence to generate vaccine candidates.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

For the new coronavirus, the company used its deoptimisation technology and designed several nCoV vaccine candidate genomes. The next step is to grow and conduct in-vivo tests of vaccine viruses before proceeding to clinical trials.

Serum Institute of India will contribute to the partnership by scaling the vaccine manufacturing.

Codagenix CEO J Robert Coleman said: “With the Serum Institute’s financial and technical support, we will be able to push a coronavirus vaccine into the clinic on an extremely rapid timeline.

“Live-attenuated vaccines like the ones developed by Codagenix are ideally suited to outbreak scenarios as they scale rapidly and generally require only modest amounts of active ingredient for each immunisation, as compared to inactivated and subunit vaccines.”

The partners have adopted an accelerated development pathway to make the vaccine available rapidly.

Serum Institute CEO Dr Adar Poonwalla said: “We are very excited for this new partnership with Codagenix and we hope that we can establish a platform dealing with new infectious diseases and outbreaks beginning with the coronavirus epidemic.”

Codagenix is among the many companies and research organisations that have initiated efforts to develop a vaccine and effective treatments for the new coronavirus that emerged in China.